Sabre Corpo (SABR)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	-278,759	-300,520	-445,986	-500,157	-528,040	-590,852	-516,722	-585,525	-444,099	-471,524	-572,611	-625,731	-928,469	-1,047,488	-1,122,465	-1,320,742	-1,272,744	-956,938	-582,907	-110,938
Total stockholders’ equity	US$ in thousands	-1,378,860	-1,270,290	-1,504,870	-1,443,900	-1,388,480	-1,294,880	-1,095,220	-960,033	-884,327	-742,964	-616,773	-447,048	-508,907	-363,762	-167,763	24,227	355,604	631,999	316,722	673,340
ROE		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-5,451.53%	-357.91%	-151.41%	-184.04%	-16.48%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-278,759K ÷ $-1,378,860K
= —

Sabre Corpo has experienced significant fluctuations in its return on equity (ROE) over the past few quarters. The ROE figures provided indicate negative values for each reporting period, suggesting that the company's net income is insufficient to cover its equity base.

The ROE values for Sabre Corpo range from -16.48% to -5,451.53%, indicating a substantial decline in performance over time. The most recent ROE figure of -5,451.53% for March 31, 2021, is particularly alarming and indicates a severe lack of profitability relative to the equity invested in the company.

Furthermore, the data shows that ROE figures are unavailable for the subsequent quarters, which may suggest that the company's financial performance has not improved, or the data is not yet available.

Overall, the negative trend in ROE for Sabre Corpo raises concerns about the company's ability to generate returns for its shareholders and highlights potential underlying financial issues that require further investigation and remediation.